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Hepatitis C virus (HCV) is one of the major etiologic
agents of chronic liver diseases. Early and effective
screening test of HCV was developed since the virus was
first identified in 1989. The screening test of HCV is anti-
HCV antibody test by immunoassays and the infection
status is confirmed by recombinant immunoblot assay
(RIBA) and nucleic acid testing of HCV.
Anti-HCV test was firstly developed by enzyme-linked
immunosorbent assay which has relatively good
sensitivity and specificity. Recently, it has been replaced
by automated chemiluminescent immunoassay (CLIA)
because of laboratory automation trend and advantages of
its improved sensitivity and specificity. But, sometimes
the screening immunoassays have been too much
improved their sensitivities. Especially among populations
with low (<10%) prevalence of HCV infection, assays for
anti-HCV antibodies show high false-positive rates [1].
This is particularly problematic in asymptomatic persons
with no clinical information available or in those who are
being tested for the first time and in determining the need
for postexposure follow-up. Therefore, positive results for
HCV antibody screening tests require confirmation with
other more specific supplementary tests such as RIBA or a
nucleic acid test [2]. 
However, some laboratories lack an established
laboratory standard for such supplemental testing or lack
understanding of performance and interpretation of the
screening and supplemental HCV tests. The high cost of
the supplemental tests also makes them unavailable in
many laboratories. One of the simple methods is sample
Signal-to-Cutoff (S/CO) ratio of anti-HCV immunoassay.
So the Center for Disease Control and Prevention (CDC)
published guidelines that recommended supplemental
tests to be based on anti-HCV assay S/CO ratios [2].
Generally, the S/CO value of more than 1 is regarded as
positive in CLIA test. However, owing to improvement in
the sensitivity of HCV tests, it is suggested that more
accurate standard for reflecting positive HCV infection is
needed. Thus, establishing optimal S/CO ratio is
prerequisite for avoiding unnecessary further HCV tests
which are currently adopted for increasing the reliability
of diagnosis. In this regard, S/CO ratio is thought to better
reflect HCV infection status of patients.
However, significant value of S/CO ratio determining
true infection status seems to be different from company
to company. Thus, the difference in the ratio from
reagents should be taken into account when judging HCV
viremia.
According to the CDC guideline, reflex supplemental
testing may be limited to screening test-positive patients
with average S/CO ratios <3.8, as anti-HCV positive
samples with average S/CO ratios ≥3.8 would be highly
predictive of the RIBA positivity (≥95%) [2]. Other studies
have also evaluated the clinical significance of low S/CO
ratios and found good correlation between S/CO ratio of
anti-HCV and HCV viremia [3-8]. Some studies even
suggested the elimination of reflex supplemental testing in
samples with low S/CO ratio in order to save costs and
reduce unnecessary testing [5,8]. These time and cost
saving efforts have been reflected in another way in the
study by Seo et al. They evaluated the utility of low S/CO
ratio in predicting HCV viremia and in deciding whether
to opt for qualitative or quantitative HCV RNA test in a
HCV antibody positive patient. The authors suggest the
use of qualitative HCV RNA testing in patients with anti-
HCV S/CO ratio <10.9 and quantitative HCV RNA testing
in patients with anti-HCV ≥10.9. This is a novel approach
to reduce time and cost of diagnosis, but unfortunately,
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may not yet be universally applicable. 
The authors of this article Seo et al. have based their
cutoff point for the S/CO ratio on results from Abbott
second-generation anti-HCV enzyme immunoassay, so
cutoff points with other enzyme immunoassays or
chemiluminescence immunoassays should be further
evaluated for application in other laboratory settings. In
addition, anti-HCV titer may decrease with spontaneous
HCV resolution or clearance after therapy [9]. In this case,
low anti-HCV S/CO ratio may not automatically require a
qualitative RNA testing and clinicians must be aware of
such influence on serologic testing. As mentioned in the
discussion, the study may be subjected to selection bias
due to the inclusion and exclusion criteria and may not be
quite applicable in patients with chronic hepatitis or HCV
resolution with or without therapy. Furthermore, the
authors have discussed that the lower detection limit of
the HCV qualitative test may possibly have misclassified
the patients and influenced the results. With development
of transcription mediated amplification assays, the
sensitivity of qualitative assays has been improved to have
a lower detectable limit of 5 IU/mL [10]. This may be
another factor influencing the clinical application of the
S/CO ratio.
Although the CDC and others have examined the
correlation of S/CO ratio and RIBA results, the high cost
and indeterminate results not infrequently seen in the
gray zone of anti-HCV titer may render the RIBA assay
obsolete as supplemental verification test [11]. The Vitros
Anti-HCV assay has been approved by the Food and Drug
Administration and an S/CO ratio of 8.0 was set as the
screening test positive value to determine the need for
reflex supplemental tests. But, a study performed in my
laboratory, the cutoff of S/CO ratios were as follows:
Elecsys assay, ≥200 (95.7%); Architect assay, ≥3 (94.9%);
Vitros assay, ≥7.0 (95.7%); Access assay, ≥3 (94.7%) [6].
Details of the four automated CLIA reagents were the
Elecsys Anti-HCV assay on the Cobas e 411 analyzer
(Roche Diagnostics, Mannheim, Germany), the Architect
Anti-HCV assay on the Architect i2000 system (Abbott
Laboratories, Abbott Park, IL, USA), the Vitros Anti-HCV
assay on the Vitros ECiQ Immunodiagnostic System
(Ortho-Clinical Diagnostics, Raritan, NJ, USA), and the
Access HCV Ab PLUS assay (Bio-Rad Laboratories,
Redmond, WA, USA) on the UniCel DxI 800 analyzer
(Beckman-Coulter, Fullerton, CA, USA).
Nucleic acid tests with improved sensitivity may
supplant former diagnostic tools, but remain expensive
and unavailable in many clinical settings. A guidance for
the optimal diagnostic approach is necessary and may
be found in the S/CO ratio of HCV antibody screening
test, but further evaluation is needed for broader clinical
application. Because many commercial reagents are on
the market and accurate correlation studies with clinical
conditions are needed. 
The paper of Seo et al. showed that S/CO ratio is
valuable in determining HCV viremia. Furthermore, they
proposed the critical level of S/CO which may help
discriminate the occasions when HCV RNA quantitative
or qualitative test are needed. These results may be
applicable effectively to detect HCV viremia for users of
the same test method. Although their results are
promising in terms of setting-up new index for HCV
viremia, further studies are needed to each laboratory to
develop their own index for their diagnostic methods. In
addition, optimization of follow-up setting for their
studies is expected. (Korean J Intern Med 2009;24:
299-301)
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